Silverarc Capital Management’s Radiopharm Theranostics RADX Stock Holding History

Silverarc Capital Management’s Portfolio RADX Stock Details RADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-187,406	Closed	-$806K	–	96
2026 Q1	$806K	Hold	187,406	–	–	0.08%	68
2025 Q4	$978K	Hold	187,406	–	–	0.14%	62
2025 Q3	$1.03M	Hold	187,406	–	–	0.14%	68
2025 Q2	$870K	Hold	187,406	–	–	0.16%	55
2025 Q1	$901K	Hold	187,406	–	–	0.18%	63
2024 Q4	$841K	Buy	+187,406	New	+$1.23M	0.18%	55

Other funds holding RADX

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return

Regal Partners Sydney, NSW, Australia $1.81B AUM 52.11% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Silverarc Capital Management's RADX Position: Q2 2026 in Review

Silverarc Capital Management sold out of Radiopharm Theranostics (RADX) in Q2 2026, closing a stake of 187,406 shares — an estimated $806K sold.

Silverarc Capital Management first reported a position in RADX in Q4 2024 and held it in 6 quarters. The position peaked at $1.03M in Q3 2025. 6 funds tracked by Wall St. Rank hold RADX as of Q2 2026.

Silverarc Capital Management reported no remaining Radiopharm Theranostics position as of Q2 2026 after selling out during the quarter.
Silverarc Capital Management sold 187,406 Radiopharm Theranostics shares in Q2 2026, an estimated $806K.
Silverarc Capital Management first reported a position in Radiopharm Theranostics in Q4 2024 and held it in 6 quarters.
Silverarc Capital Management's Radiopharm Theranostics position peaked at $1.03M in Q3 2025.
6 funds tracked by Wall St. Rank held Radiopharm Theranostics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.